Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 2/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.42 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | TLR2 | O60603 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28232408 | 1.00 | PRCP (0.43) | PRCPSCN9ASCN3ASCN5ADPP7 | |
| SCHEMBL7299117 | 1.00 | PRCP (0.43) | PRCPSCN9ASCN3ASCN5ADPP7 | |
| SCHEMBL3610491 | 0.95 | SCN9A (0.39) | PRCPSCN9ASCN3ASCN5ADPP7 | |
| SCHEMBL4630085 | 0.95 | SCN9A (0.39) | PRCPSCN9ASCN3ASCN5ADPP7 | |
| SCHEMBL3597014 | 0.92 | PRCP (0.39) | PRCPSCN9ASCN3ASCN5ABTK | |
| SCHEMBL6872992 | 0.92 | PRCP (0.39) | PRCPSCN9ASCN3ASCN5ABTK | |
| SCHEMBL4615012 | 0.83 | PRCP (0.47) | PRCPDPP7HTR2CTLR2KDM4E | |
| SCHEMBL13767206 | 0.82 | PRCP (0.56) | PRCPSCN9ASCN3ASCN5ADPP7 | |
| SCHEMBL5154183 | 0.80 | GAA (0.38) | PRCPSCN9ASCN3ASCN5ABTK | |
| SCHEMBL7345915 | 0.80 | PRCP (0.64) | PRCPDPP7HTR2CTLR2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119059954-A | Synthesis and preparation method of vildagliptin | 苏州翔实医药发展有限公司 | 2024-12-03 | — | — | CN | claimed |
| CN-112028806-B | Synthetic method of vildagliptin intermediate | 河北合佳医药科技集团股份有限公司 | 2022-09-30 | — | — | CN | claimed |
| CN-119059954-A | Synthesis and preparation method of vildagliptin | 苏州翔实医药发展有限公司 | 2024-12-03 | — | — | CN | disclosed |
| CN-118812520-A | Benzimidazole-6-carboxylic acid compound and application thereof | 南京羚诺生物医药技术研究院有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-112028806-B | Synthetic method of vildagliptin intermediate | 河北合佳医药科技集团股份有限公司 | 2022-09-30 | — | — | CN | disclosed |
| CN-112028806-B | Synthetic method of vildagliptin intermediate | 河北合佳医药科技集团股份有限公司 | 2022-09-30 | — | — | CN | disclosed |
| US-20170129916-A1 | NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2017-05-11 | — | — | US | disclosed |
| EP-2431037-B1 | (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms, and methods of use thereof | ATTENUA INC (US) | 2016-11-30 | — | — | EP | disclosed |
| EP-2465501-B1 | Method for the preparation of (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide | ATTENUA INC (US) | 2016-10-05 | — | — | EP | disclosed |
| US-20150045386-A1 | (2S,3R)-N-2-3-PYRIDINYLMETHYL-1-AZABICYCLO 2.2.2 OCT-3-YL BENZOFURAN-2-CARBOXAMIDE, NOVEL SALT FORMS, AND METHODS OF USE THEREOF | ATTENUA, INC. | 2015-02-12 | — | — | US | disclosed |
| US-8846715-B2 | (2S,3R)-N-(2((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide novel salt forms, and methods of use thereof | TARGACEPT, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20080138287-A1 | 3-SUBSTITUTED-2(ARYLALKYL)-1- AZABICYCLOALKANES AND METHODS OF USE THEREOF | ATTENUA, INC. | 2008-06-12 | — | — | US | disclosed |
| EP-1594869-B1 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF | TARGACEPT INC (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20060247270-A1 | e.g. 2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl N-phenylcarbamate; nicotinic acetylcholine receptors alpha 7 (nAChRs)/neurotransmitter modulator; diagnostic radiolabel; central nervous systrem disorders, autoimmune diseases; antiinflammatory, antitumor agents, angiogenesis inhibitor | ATTENUA, INC. | 2006-11-02 | — | — | US | disclosed |
| CN-1751041-A | 3-substituted-2- (arylalkyl) -1-azabicycloalkanes and methods of use thereof | TARGACEPT INC (US) | 2006-03-22 | — | — | CN | disclosed |
| US-20050255040-A1 | 3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | ATTENUA, INC. | 2005-11-17 | — | — | US | disclosed |
| EP-1594869-A2 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF | Targacept, Inc. (US) | 2005-11-16 | — | — | EP | disclosed |
| US-6953855-B2 | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2005-10-11 | — | — | US | disclosed |
| WO-2004076449-A2 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF | TARGACEPT, INC. (US) | 2004-09-10 | — | — | WO | disclosed |
| US-20040002513-A1 | 3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | ATTENUA, INC. | 2004-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080138287-A1 | 3-SUBSTITUTED-2(ARYLALKYL)-1- AZABICYCLOALKANES AND METHODS OF USE THEREOF | CHRNA7, CHRNA5, CHRNA3 | PRCP 3403/4885SCN9A 775/4885SCN3A 197/4885 |
| US-20170129916-A1 | NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS | BET1, PRR12, PREP | PRCP 501/4885SCN9A 4678/4885SCN3A 4772/4885 |
| US-20060247270-A1 | e.g. 2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl N-phenylcarbamate; nicotinic acetylcholine receptors alpha 7 (nAChRs)/neurotransmitter modulator; diagnostic radiolabel; central nervous systrem disorders, autoimmune diseases; antiinflammatory, antitumor agents, angiogenesis inhibitor | CHRM1, CHRNA7, CHRM3 | PRCP 3305/4885SCN9A 134/4885SCN3A 27/4885 |
| US-20150045386-A1 | (2S,3R)-N-2-3-PYRIDINYLMETHYL-1-AZABICYCLO 2.2.2 OCT-3-YL BENZOFURAN-2-CARBOXAMIDE, NOVEL SALT FORMS, AND METHODS OF USE THEREOF | HCN3, HCN2, NTSR2 | PRCP 3398/4885SCN9A 402/4885SCN3A 8/4885 |
| US-20040002513-A1 | 3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | CHRNA7, CHRNA3, CHRNA1 | PRCP 3356/4885SCN9A 874/4885SCN3A 174/4885 |
| US-20050255040-A1 | 3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | CHRNA7, CHRNA3, CHRNA5 | PRCP 3341/4885SCN9A 866/4885SCN3A 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.